Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2009 1
2014 1
2015 1
2018 1
2019 1
2020 1
2021 1
2022 1
2023 1
2025 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

9 results

Results by year

Filters applied: . Clear all
Your search was processed without automatic term mapping because it retrieved zero results.
The following term was not found in PubMed: /
Page 1
Clinical review: Drugs commonly associated with weight change: a systematic review and meta-analysis.
Domecq JP, Prutsky G, Leppin A, Sonbol MB, Altayar O, Undavalli C, Wang Z, Elraiyah T, Brito JP, Mauck KF, Lababidi MH, Prokop LJ, Asi N, Wei J, Fidahussein S, Montori VM, Murad MH. Domecq JP, et al. J Clin Endocrinol Metab. 2015 Feb;100(2):363-70. doi: 10.1210/jc.2014-3421. Epub 2015 Jan 15. J Clin Endocrinol Metab. 2015. PMID: 25590213 Free PMC article.
Weight gain was associated with the use of amitriptyline (1.8 kg), mirtazapine (1.5 kg), olanzapine (2.4 kg), quetiapine (1.1 kg), risperidone (0.8 kg), gabapentin (2.2 kg), tolbutamide (2.8 kg), pioglitazone (2.6 kg), glimepiride (2.1 kg), gliclazide (1.8 kg), glyburide ( …
Weight gain was associated with the use of amitriptyline (1.8 kg), mirtazapine (1.5 kg), olanzapine (2.4 kg), quetiapine (1.1 kg), risperido …
Glimepiride reduces CD14 expression and cytokine secretion from macrophages.
Ingham V, Williams A, Bate C. Ingham V, et al. J Neuroinflammation. 2014 Jun 21;11:115. doi: 10.1186/1742-2094-11-115. J Neuroinflammation. 2014. PMID: 24952384 Free PMC article.
CD14 is a glycosylphosphatidylinositol (GPI)- anchored protein that is part of a receptor complex that mediates microglial responses to peptides that accumulate in prion disease (PrP82-146), AD (amyloid-beta (Abeta)42) and PD (alpha-synuclein (alphaSN)). As some GPI-anchor …
CD14 is a glycosylphosphatidylinositol (GPI)- anchored protein that is part of a receptor complex that mediates microglial responses to pept …
Pharmacokinetic/Pharmacodynamic Interactions Between Evogliptin and Glimepiride in Healthy Male Subjects.
Yoo H, Kim Y, Jang IJ, Yu KS, Lee S. Yoo H, et al. Drug Des Devel Ther. 2020 Nov 24;14:5179-5187. doi: 10.2147/DDDT.S275343. eCollection 2020. Drug Des Devel Ther. 2020. PMID: 33262578 Free PMC article. Clinical Trial.
PURPOSE: Evogliptin, a dipeptidyl peptidase-4 inhibitor, and glimepiride, a sulfonylurea, are used to treat type 2 diabetes mellitus. In this study, we aimed to evaluate the pharmacokinetic (PK) and pharmacodynamic (PD) interactions between evogliptin and glimepi …
PURPOSE: Evogliptin, a dipeptidyl peptidase-4 inhibitor, and glimepiride, a sulfonylurea, are used to treat type 2 diabetes mellitus. …
Glimepiride Prevents 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine Induced Dopamine Neurons Degeneration Through Attenuation of Glia Activation and Oxidative Stress in Mice.
Oduola-Akande MD, Ishola IO, Olubodun-Obadun TG, Akande AJ, Adeyemi OO. Oduola-Akande MD, et al. Neurotox Res. 2023 Jun;41(3):212-223. doi: 10.1007/s12640-023-00637-4. Epub 2023 Jan 27. Neurotox Res. 2023. PMID: 36705862
This study evaluated the effect of glimepiride (GMP), a third generation sulphonylurea, on 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced PD in mice. ...Thus, this could be useful as a disease-modifying therapy in the management of PD....
This study evaluated the effect of glimepiride (GMP), a third generation sulphonylurea, on 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridi …
Glimepiride prevents paraquat-induced Parkinsonism in mice: involvement of oxidative stress and neuroinflammation.
Ishola IO, Akataobi OE, Alade AA, Adeyemi OO. Ishola IO, et al. Fundam Clin Pharmacol. 2019 Jun;33(3):277-285. doi: 10.1111/fcp.12434. Epub 2018 Dec 7. Fundam Clin Pharmacol. 2019. PMID: 30451327
There is a growing number of epidemiological and molecular studies which suggest that diabetes is associated with an increased risk of Parkinson's disease (PD). Hence, in this study, the effect of glimepiride (GPD), a sulphonylurea (antidiabetic) on paraquat (PQT)-i …
There is a growing number of epidemiological and molecular studies which suggest that diabetes is associated with an increased risk of Parki …
Long-term effects of dapagliflozin plus saxagliptin versus glimepiride on a background of metformin in patients with type 2 diabetes: Results of a 104-week extension to a 52-week randomized, phase 3 study and liver fat MRI substudy.
Frías JP, Maaske J, Suchower L, Johansson L, Hockings PD, Iqbal N, Wilding JPH. Frías JP, et al. Diabetes Obes Metab. 2022 Jan;24(1):61-71. doi: 10.1111/dom.14548. Epub 2021 Sep 28. Diabetes Obes Metab. 2022. PMID: 34514692 Free PMC article. Clinical Trial.
AIM: To report the results of a 104-week extension to a 52-week study in which dapagliflozin plus saxagliptin (DAPA+SAXA) improved glycaemic control, liver fat and metabolic variables compared with glimepiride (GLIM) in participants with type 2 diabetes (T2D) receiving bac …
AIM: To report the results of a 104-week extension to a 52-week study in which dapagliflozin plus saxagliptin (DAPA+SAXA) improved glycaemic …
Pharmacokinetic and pharmacodynamic modelling of the effects of glimepiride on insulin secretion and glucose lowering in healthy humans.
Yun HY, Park HC, Kang W, Kwon KI. Yun HY, et al. J Clin Pharm Ther. 2006 Oct;31(5):469-76. doi: 10.1111/j.1365-2710.2006.00766.x. J Clin Pharm Ther. 2006. PMID: 16958825 Clinical Trial.
Glimepiride is an oral sulfonylurea antihyperglycaemic agent. We used pharmacokinetic-pharmacodynamic (PK-PD) modelling to analyse the relationship between plasma glimepiride concentration, insulin secretion and glucose lowering to determine the effects of th …
Glimepiride is an oral sulfonylurea antihyperglycaemic agent. We used pharmacokinetic-pharmacodynamic (PK-PD) modelling to ana …
The Clinical Pharmacokinetics and Pharmacodynamics of Glimepiride-A Systematic Review and Meta-Analysis.
Azhar M, Alasmari MS, Zamir A, Saeed H, Alqahtani F, Ahmad T, Rasool MF. Azhar M, et al. Pharmaceuticals (Basel). 2025 Jan 17;18(1):122. doi: 10.3390/ph18010122. Pharmaceuticals (Basel). 2025. PMID: 39861183 Free PMC article.
Background/Objectives: Glimepiride (GLM), a commonly used sulphonylurea drug for the management of type 2 diabetes mellitus (T2DM), has been the subject of numerous studies exploring its kinetic behaviors. ...This systematic review aims to provide detailed knowledge about …
Background/Objectives: Glimepiride (GLM), a commonly used sulphonylurea drug for the management of type 2 diabetes mellitus (T2DM), h …
[Hypoglycemic risk of insulinotropic drugs].
Böhm R, Cascorbi I, Herdegen T. Böhm R, et al. Med Monatsschr Pharm. 2009 Dec;32(12):453-8. Med Monatsschr Pharm. 2009. PMID: 20088347 Review. German.
Orally available insulinotropics that directly close K(ATP)-channels, such as sulfonylureas and glinides, differ in their pharmacokinetics and -dynamics (PK/PD). This results in different risks for their incidence of hypoglycemic episodes. Glibenclamide (USAN: glyburide) h …
Orally available insulinotropics that directly close K(ATP)-channels, such as sulfonylureas and glinides, differ in their pharmacokinetics a …